CAR-T therapy for multiple myeloma in China. Does it make sense financially?
J Med Econ
.
2023 Jan-Dec;26(1):824-825.
doi: 10.1080/13696998.2023.2224636.
Author
Panagiotis Petrou
1
Affiliation
1
Senior Officer, Health Insurance Organization Department of Life and Health Sciences, School of Pharmacy, Pharmacoepidemiology-Pharmacovigilance, University of Nicosia, Nicosia, Cyprus.
PMID:
37306237
DOI:
10.1080/13696998.2023.2224636
No abstract available
Publication types
Editorial
MeSH terms
China
Humans
Immunotherapy, Adoptive
Multiple Myeloma* / drug therapy
Receptors, Antigen, T-Cell
Receptors, Chimeric Antigen*
Substances
Receptors, Chimeric Antigen
Receptors, Antigen, T-Cell